VERTANICAL said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, the company’s investigational non-opioid treatment for chronic low back pain, marking a significant regulatory milestone as the biotechnology firm seeks to bring an alternative to opioid-based pain management to market.
The designation follows results from two randomized, controlled Phase 3 studies in which VER-01 demonstrated significant reductions in pain, favorable tolerability and no evidence of dependence, according to the company. In one head-to-head Phase 3 comparator study, VER-01 also outperformed opioid treatments in pain reduction while showing better gastrointestinal tolerability, strengthening its position as a potential alternative to conventional chronic pain therapies.
The FDA’s Breakthrough Therapy Designation is intended to accelerate the development and regulatory review of medicines showing early evidence of substantial improvement over existing therapies for serious conditions. The status provides companies with closer regulatory interaction and expedited pathways intended to speed the delivery of promising therapies to patients.
For VERTANICAL, the designation signals growing regulatory confidence in VER-01 at a time when healthcare providers continue to search for safer and more effective chronic pain treatments amid concerns surrounding opioid dependence and abuse.
Chronic pain remains one of the largest unmet healthcare needs globally. More than one billion people worldwide are estimated to live with chronic pain, including over 60 million people in the United States. Opioids continue to play a major role in pain management, despite well-documented risks including addiction, misuse and adverse side effects.
The need for non-opioid treatment alternatives has become particularly urgent in the United States, where policymakers and healthcare systems continue to address the long-term effects of the opioid crisis. Despite the scale of the burden, pharmaceutical innovation in chronic pain treatment has lagged behind other major therapeutic areas for decades.
VER-01 is being positioned as a first-in-class investigational therapy with a novel mechanism of action designed to provide sustained pain relief without the dependency risks traditionally associated with opioid medicines.
Clemens Fischer, chief executive officer of FUTRUE Group and founder of VERTANICAL, said the FDA designation represents recognition of VER-01’s potential to address a major unmet medical need in chronic pain. He added that patients have long lacked meaningful therapeutic innovation and expressed confidence that the treatment could reshape approaches to chronic pain management.
The designation was supported by findings from VERTANICAL’s European Phase 3 clinical program in chronic low back pain. In a placebo-controlled Phase 3 study published in the medical journal Nature Medicine, VER-01 met its primary endpoint by significantly reducing pain compared with placebo, while maintaining sustained effects during long-term treatment.
The study also reported improvements in symptoms commonly associated with chronic pain, including sleep disturbances and reduced physical functioning.
In an additional comparator study, VER-01 showed greater pain reduction and improved gastrointestinal tolerability compared with opioid treatments. Across the development program, the therapy was generally well tolerated, with no signs of dependence or withdrawal symptoms reported.
VERTANICAL said it expects marketing authorization decisions in the first European countries within weeks while simultaneously advancing a new pivotal Phase 3 study in the United States designed to support a future FDA submission.
The company anticipates an initial readout from the U.S. study in 2027 and, pending positive results, plans to submit a New Drug Application to the FDA in 2028.